FUNDAMENTAL AND CLINICAL STUDIES ON DL-8280 IN THE FIELD OF UROLOGY

• Published in: CHEMOTHERAPY Vol. 32; no. Supplement1; pp. 687 - 697
• Main Authors: HARADA, MASUYOSHI, ARAKAWA, SOICHI, TADERA, SHIGENORI, UMEZU, KEIICHI, KATAOKA, NOBUMASA, KAMIDONO, SADAO, ISHIGAMI, JOJI
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1984
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.32.Supplement1_687

Fundamental and clinical studies on DL-8280, a new synthetic antimicrobial agent for oral use, were performed in the field of urology. Serum concentrations of DL-8280 at 1 and 3 hours after a single oral administration at a dose of 200mg were 1.17μg/mland 1.19μg/ml, respectively, and the highest urinary concentration of 181.3μg/ml was observed in the urine collected during 2 to 4 hours after administration and the urinary recovery was 55.1% at 24 hours after administration. MICs were determined against, clinically isolated bacteria consisting of E. coli, C. freundii, K. pneumoniae, E. cloacae, indole negative Proteus, indole positive Proteus, S. marcescens, S. liimfaciens and P. aeruginosa and were compared with those of norfloxacin, pipemidic acid and nalidixic acid. MICs of DL-8280 against all bacteria were almost the same as those of norfloxacin, and were lower than those of pipemidic acid and nalidixic acid. Overall clinical efficacy on 11 patients with acute uncomplicated cystitis was “excellent” in 7, “moderate” in 4 and the effectiveness rate was 100%. Overall clinical efficacy on 13 patients with complicated urinary tract infections were “excellent” in 8, “rroderate” in 3 and the effectiveness rate was 85%. As for side effects, 2 cases of very slight pyrosis were observed. No abnormal change in laboratory examinations was noted.